Abstract

Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets

Author(s): Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu

Issue: Mar/Apr 2014 - Volume 18, Number 2

Page(s): 169-174

Download in electronic PDF format for $75
  • Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets Page 1
  • Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets Page 2
  • Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets Page 3
  • Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets Page 4
  • Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets Page 5
  • Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets Page 6

Abstract

The aim of this study was to develop an extemporaneous valsartan suspension (80 mg valsartan/ 5 mL) starting from commercial tablets (80-mg/ tablet). A high-performance liquid chromatographic system was used for the analysis and quantification of valsartan in the samples studied. Samples of valsartan suspension for analysis were prepared as reported by the validated high-performance liquid chromatographic method and the dissolution tests were performed according to the U.S. Food and Drug Administration’s method. The high-performance liquid chromatographic assay indicated that the 80-mg/5-mL valsartan suspension was stable for 30 days when stored at long-term and accelerated storage conditions. Valsartan release profile showed that approximately 85% of valsartan dissolved after 10 minutes and, accordingly, the calculation of similarity factor was not necessary. It is possible for the pharmacist to crush valsartan 80-mg tablets and prepare a suspension which has dosage flexibility that can be calculated according to body-surface area, kidney, and liver functions, without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost-effective dosage form.

Related Keywords

  • valsartan
  • oral suspension
  • formulation
  • stability
  • Palestine

Related Categories

  • FORMULATIONS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • CARDIOLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2014
Pg. 169-174
Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Author(s): Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
May/Jun 2003
Pg. 233-239
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Author(s): Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
Mar/Apr 2016
Pg. 159-163
Stability of Commercially Available Grape and Compounded Cherry Oral Vancomycin Preparations Stored in Syringes and Cups
Author(s): Kirk Loren, Lewis Paul, Luu Yao, Brown Stacy
May/Jun 2018
Pg. 247-251
Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations
Author(s): Visser J Carolina, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J
Jan/Feb 2023
Pg. 72-77
Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Author(s): Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
May/Jun 2019
Pg. 237
Valsartan 16-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2008
Pg. 372-374
Chemical Stability of Perphenazine in Two Commercially Available Vehicles for Oral Liquid Dosage Forms
Author(s): Gupta Vishnu D
Jul/Aug 2010
Pg. 342-345
Evaluation of Extemporaneous Oral Itraconazole Suspensions by Dissolution Profiles Mapping
Author(s): Tong Henry H Y, Chan Hokman, Du Zhen, Zheng Ying
Mar/Apr 2017
Pg. 160-163
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Author(s): Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Jul/Aug 2017
Pg. 322-329
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Sep/Oct 2021
Pg. 431-439
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Mar/Apr 1997
Pg. 128-131
Stability of Allopurinol Suspension Compounded from Tablets
Author(s): Alexander Kenneth S, Davar Nipun, Parker Gordon A
Jan/Feb 2018
Pg. 66-75
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
Author(s): Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
Sep/Oct 2018
Pg. 433-439
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding
Author(s): Zhao Fang, Dave Vivek S, Mar Mazin Z, Perri Jonathan R
Jan/Feb 2001
Pg. 9-12
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Author(s): Schotik Debora
Sep/Oct 2006
Pg. 396-399
Temozolomide Stability in Extemporaneously Compounded Oral Suspensions
Author(s): Trissel Lawrence A, Zhang Yanping, Koontz Susannah E
Jul/Aug 2021
Pg. 329
Valsartan 4-mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 523-527
Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution
Author(s): Zaid Abdel-Naser, Zaaror Yara Abu, Qaddumi Aiman, Ratrout Ala, Ahmad Ayda, Hamad Emad, Kittana Naim